Validus Pharma gets rights to six Novartis drugs in USA

19 November 2012

USA-based Validus Pharmaceuticals (NYSE: VR) together with Wood Creek Capital Management, have acquired USs rights to six well-known product lines, patent protection on which has now expired, from the US subsidiary of Swiss drug major Novartis (NOVN: VX). No financial terms were revealed.

The products in questions are: Lopressor (metoprolol tartrate USP) but excluding Lopressor (metoprolol tartrate) Injection, Lopressor HCT (metoprolol tartrate USP + hydrochlorothiazide USP), Lotensin (benazepril HCl), Lotensin HCT (benazepril HCl + hydrochlorothiazide USP), Parlodel (bromocriptine mesylate USP) and Methergine (methylergonovine maleate).

Wood Creek acquired the Novartis products on August 29, 2012 through a new company, US Pharmaceuticals Holdings. Validus will serve as the exclusive manager for the ex-Novartis lines. These products present Validus with opportunities to generate sales in several new therapeutic markets and represent a significant growth catalyst for the company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK